The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the ...

Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural ...

U.S. President Donald Trump listens to remarks during a swearing-in ceremony for Administrator of the Centers for Medicare ...

The Trump administration is planning an experiment to cover weight-loss drugs under Medicare and Medicaid, the Washington ...

Medicare is on shaky ground in the current policy environment, making it difficult to sustain its accomplishments, much less ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

The federal government's Medicare program and older adults together spend $4.4 billion a year on care that has low clinical ...

Thousands of Rhode Island seniors and disabled residents no longer covered for non-emergency visits at four local hospitals ...

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...